Amneal Pharmaceuticals (DB:2DT) - Prezzo delle azioni, notizie e analisi

2DT Panoramica delle azioni

2DT analisi fondamentale
Punteggio fiocco di neve
Valutazione	6/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Negoziato a 81.8% al di sotto della nostra stima del suo valore equo

Si prevede che i ricavi cresceranno 5.57% all'anno

Negoziato a un buon valore rispetto ai pari e al settore

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 24%

Analisi del rischio

Patrimonio netto negativo

Prezzo delle azioni volatile negli ultimi 3 mesi

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Amneal Pharmaceuticals, Inc. Concorrenti

Dermapharm Holding

XTRA:DMP

€1.9b

Bayer

XTRA:BAYN

€19.9b

PharmaSGP Holding

XTRA:PSG

€297.4m

Pierrel

DB:2FJ0

€92.8m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Amneal Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$8.05
Massimo di 52 settimane	US$8.55
Minimo di 52 settimane	US$3.80
Beta	1.17
1Variazione di 1 mese	5.23%
Variazione a 3 mesi	17.52%
Variazione di 1 anno	102.26%
3Variazione a 3 anni	101.25%
Variazione a 5 anni	198.15%
Variazione dall'IPO	-56.27%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	2DT	DE Pharmaceuticals	DE Mercato
7D	5.9%	-7.5%	-0.2%
1Y	102.3%	-24.1%	8.3%

Ritorno vs Industria: 2DT ha superato il German Pharmaceuticals che ha restituito -24.1 % nell'ultimo anno.

Rendimento vs Mercato: 2DT ha superato il mercato German che ha restituito 8.3 % nell'ultimo anno.

Volatilità dei prezzi

Is 2DT's price volatile compared to industry and market?
2DT volatility
2DT Average Weekly Movement	7.1%
Pharmaceuticals Industry Average Movement	8.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di 2DT è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 7% ) di 2DT è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2002	7,850	Chirag Patel	amneal.com

Amneal Pharmaceuticals, Inc. insieme alle sue consociate, sviluppa, produce, commercializza e distribuisce in tutto il mondo farmaci generici, iniettabili, biosimilari e specialità farmaceutiche di marca. L'azienda opera attraverso tre segmenti: Generici, Specialità e AvKARE. Il segmento Generics offre prodotti orali solidi, in polvere, liquidi, iniettabili sterili, spray nasali, inalatori e respiratori, biosimilari, oftalmici, film, cerotti transdermici e prodotti topici a rilascio immediato ed esteso.

Amneal Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Amneal Pharmaceuticals con la sua capitalizzazione di mercato?
2DT statistiche fondamentali
Capitalizzazione di mercato	€2.65b
Guadagni(TTM)	-€175.21m
Ricavi(TTM)	€2.55b

1.0x

Rapporto P/S

-14.2x

Rapporto P/E

2DT è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
2DT Conto economico (TTM)
Ricavi	US$2.68b
Costo del fatturato	US$1.70b
Profitto lordo	US$979.05m
Altre spese	US$1.16b
Guadagni	-US$184.45m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.60
Margine lordo	36.53%
Margine di profitto netto	-6.88%
Rapporto debito/patrimonio netto	-7,524.6%

Come si è comportato 2DT nel lungo periodo?

Vedi performance storica e confronto

2DT Panoramica delle azioni

Premi

Analisi del rischio

Amneal Pharmaceuticals, Inc. Concorrenti

XTRA:DMP

€1.9b

XTRA:BAYN

€19.9b

XTRA:PSG

€297.4m

DB:2FJ0

€92.8m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold €703k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold €703k worth of stock

Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant

Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies

Independent Director recently sold €236k worth of stock

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.86 loss in FY 2022)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Third quarter 2023 earnings released: EPS: US$0.063 (vs US$0.018 loss in 3Q 2022)

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Second quarter 2023 earnings released: EPS: US$0.078 (vs US$0.80 loss in 2Q 2022)

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Insufficient new directors

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$0.86 loss per share (vs US$0.071 profit in FY 2021)

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Insufficient new directors

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

Third quarter 2022 earnings released: US$0.018 loss per share (vs US$0.028 loss in 3Q 2021)

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022

Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection

Amneal Pharmaceuticals, Inc. Announces Management Changes

Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS

Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty

Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.098 profit in 2Q 2021)

Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022

High number of new directors